Lamartine Conseil and HPML advised on the deal. Bryan Cave Leighton Paisner advised the senior lenders in the acquisition of Biomega medical biology laboratories by the Bioclinic group. McDermott Will & Emery advised Andera Partners.
The closing of this transaction involving numerous parties was signed 100 percent electronically.
The transaction was partly financed by a reinvestment of the financial investors who have supported the Bioclinic group since 2018, with Idia Capital Investissement, Socadif and Andera Partners (via Actomezz) and by a banking pool including Crédit Lyonnais, as arranger and agent, with Erik Pebreuil and Lucile Hellot, Banque Neuflize OBC, BNP Paribas, Caisse d’Epargne Ile-de-France, Société Générale and Zencap Asset Management. Some of the biologists also are reinvesting in the group.
Bioclinic is now in charge of 86 laboratories and five technical platforms spread over Ile-de-France.
Lamartine Conseil advised Bioclinic with Fabien Mauvais, Valentine Berquet (M&A) et Emilie Renaud (Tax).
HPML advised the sellers with Thomas Hermetet.
Bryan Cave Leighton Paisner’s deal team was led by Paris Partner Olivier Borenstejn (Picture), with support from Associate Emmanuel Le Galloc’h for the financing aspects.
McDermott Will & Emery advised Andera Partners with Pierre-Arnoux Mayoly and Benjamin Briand.
Involved fees earner: Olivier Borenstejn – Bryan Cave Leighton Paisner; Emmanuel Le Galloc’h – Bryan Cave Leighton Paisner; Thomas Hermetet – HPML Avocats; Valentine Berquet – Lamartine Conseil; Fabien Mauvais – Lamartine Conseil; Emilie Renaud – Lamartine Conseil; Benjamin Briand – McDermott Will & Emery; Pierre-Arnoux Mayoly – McDermott Will & Emery;